Abstract
魏明伟,李靖欣,储凯,朱加宏,朱凤才.b型流感嗜血杆菌结合疫苗接种后5年的免疫持久性观察[J].Chinese journal of Epidemiology,2022,43(11):1768-1772
b型流感嗜血杆菌结合疫苗接种后5年的免疫持久性观察
Five-year immunity persistence following immunization with haemophilus influenzae type b conjugate vaccine
Received:May 26, 2022  
DOI:10.3760/cma.j.cn112338-20220526-00467
KeyWord: b型流感嗜血杆菌  疫苗  免疫持久性
English Key Word: Haemophilus influenzae type b  Vaccine  Immunity persistence
FundProject:
Author NameAffiliationE-mail
Wei Mingwei Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China  
Li Jingxin Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China  
Chu Kai Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China  
Zhu Jiahong Program Office, Lianshui County Center for Disease Control and Prevention, Huai'an 223499, China  
Zhu Fengcai Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China jszfc@vip.sina.com 
Hits: 2195
Download times: 847
Abstract:
      目的 评价国产b型流感嗜血杆菌(Hib)结合疫苗在我国3月龄至5岁健康婴幼儿接种后5年的免疫持久性。方法 选择江苏省涟水县Ⅲ期临床试验(试验疫苗组)中完成全程免疫接种者作为研究对象,2019年11-12月开展接种后5年的采血工作,并采用ELISA法检测血清抗b型流感嗜血杆菌-荚膜多糖(Hib-PRP)抗体,计算血清抗Hib-PRP抗体长期保护率和短期保护率、几何平均浓度(GMC)和几何平均浓度增长倍数(GMFI)。结果 共纳入研究对象580例,其中3~5月龄组、6~11月龄组以及1~5岁组分别有158、207和215例,各年龄组接种后5年的血清抗PRP抗体的短期保护率(≥0.15 μg/ml)和长期保护率(≥1.0 μg/ml)均分别为89.24%、90.34%和98.60%,GMC分别为3.95、3.11和10.01 μg/ml,GMFI分别为29.04、11.01和3.26。结论 在3月龄至5岁的婴幼儿中Hib结合疫苗接种后5年仍具有良好的免疫持久性。
English Abstract:
      Objective To evaluate the immunity persistence five years later after immunization with Haemophilus influenzae type b (Hib) conjugate vaccine in healthy infants/children aged 3 months to 5 years in China. Methods The children were subjects who completed the whole-schedule immunization in the phase Ⅲ clinical trial in Lianshui county of Jiangsu povince was selected for the collection of blood samples at 5 years after vaccination from November to December, 2019. The enzyme-linked immunosorbent assay (ELISA) was used to detect Hib polyribosyl-ribitol-phosphate antibody (anti-Hib-PRP), and the long-term/short-term protection rate, geometric mean concentration (GMC) and geometric mean concentration increase fold (GMFI) of serum anti-Hib-PRP were calculated. Results A total of 580 children were enrolled in this study, of which 158, 207 and 215 belonged to 3-5 month age group, 6-11 month age group and 1-5 year age group, respectively. The short-term (≥ 0.15 μg/ml)/long-term (≥ 1.0 μg/ml) protection rates of serum anti-PRP in the three groups after immunization were 89.24%, 90.34% and 98.60%, respectively; the GMC were 3.95 μg/ml, 3.11 μg/ml and 10.01 μg/ml respectively, and the GMFI were 29.04, 11.01 and 3.26 respectively. Conclusions Hib conjugate vaccine can still have good immunogenicity after 5 years of primary immunization in healthy infants/children aged 3 months to 5 years in China.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close